论文信息 - A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER). - 字舞流文

A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).

A. Grothey | A. Cercek | M. Fakih | T. Bekaii-Saab | D. Niedzwiecki | Christina Wu | K. Ng | J. Strickler | S. Peterson | F. Sanchez | Lorelei A. Bandel | Tyler Zemla | Lorelei A Bandel